FA info icon.svg Angle down icon.svg Medical equipment data
Health topic Tuberculosis
Health classification Diagnosis
Treatment
Font Awesome map marker.svg Angle down icon.svg Location data
Loading map...
Location Philadelphia, United States

Problem being addressed[edit | edit source]

Once a patient is known to be infected with tuberculosis (TB), the next step is providing anti-TB drugs to treat the disease. However, some TB patients poorly absorb these drugs, leading to inadequate treatment the infection.

Detailed description of the solution[edit | edit source]

Vinnard proposes to develop a low-cost urine test to measure the bioavailability (the amount of the drug that is absorbed) of anti-TB drugs in patients with TB. The proposed test will be point-of-care, safe, accurate, and inexpensive, making it viable in resource-limited settings. Specifically, the project will evaluate urine colorimetry, "a technique used to determine the concentration of colored compounds in a solution by measuring its absorbance of a specific wavelength of light."

Designed by[edit | edit source]

  • Designed by: Primary Investigator is Christopher Vinnard, Drexel University
  • Manufacturer (if different): n/a
  • Manufacturer location: Philadelphia, PA, USA

Funding Source[edit | edit source]

Received grant from Grand Challenges Exploration in Global Health (May 2012).

References[edit | edit source]

Other internally generated reports[edit | edit source]

Externally generated reports[edit | edit source]

FA info icon.svg Angle down icon.svg Page data
SDG SDG03 Good health and well-being
Authors D. Hodgson
License CC-BY-SA-3.0
Language English (en)
Related 0 subpages, 1 pages link here
Aliases Drug Bioavailability
Impact 188 page views
Created August 27, 2014 by D. Hodgson
Modified April 21, 2023 by Felipe Schenone
Cookies help us deliver our services. By using our services, you agree to our use of cookies.